Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 154)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Endostatins |
|
Phase 4 |
|
|
|
2 |
|
Endostar protein |
|
Phase 4 |
|
|
|
3 |
|
Vinorelbine |
Approved, Investigational |
Phase 3 |
|
71486-22-1 |
44424639 60780 |
Synonyms:
5' Nor anhydrovinblastine
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
Navelbine
Navelbine Base
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
|
Vinorelbine
VINORELBINE BASE
Vinorelbine bitartrate
Vinorelbine ditartarate
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
4 |
|
Afatinib |
Approved |
Phase 3 |
|
439081-18-2, 850140-72-6 |
53445376 10184653 |
Synonyms:
AFATINIB
AFATINIBUM
BIBW 2992
BIBW2992
BIBW-2992
|
BIBW2992|Gilotrif®
GILOTRIF
GIOTRIF
Tomtovok
Tovok
|
|
5 |
|
Gemcitabine |
Approved |
Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
6 |
|
Ipilimumab |
Approved |
Phase 2, Phase 3 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
7 |
|
Cetuximab |
Approved |
Phase 3 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
8 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
9 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
10 |
|
Pemetrexed |
Approved, Investigational |
Phase 3 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
11 |
|
Erlotinib |
Approved, Investigational |
Phase 3 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
12 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
13 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
14 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
15 |
|
Xylometazoline |
Approved, Investigational |
Phase 3 |
|
526-36-3 |
5709 |
Synonyms:
2-(4'-Tert-butyl-2',6'-dimethylphenylmethyl)imidazoline
Amidrin
Balkis
Balminil
Chlorohist-la
Decongest
Espa-rhin
Gelonasal
Idasal
Idril N
Imidin
Nasan
Nasengel al
NasenGel ratiopharm
Nasenspray al
NasenSpray ratiopharm
Nasentropfen al
NasenTropfen ratiopharm
|
Novorin
Otradrops
Otraspray
Otriven
Otrivin
Otrivin mentol
OTRIVINE
Otrivine®|xylomethazoline
OTV391
Rapako
Schnupfen endrine
Snup
Stas
Xylometazoline
Xylometazoline hydrochloride
Xylometazoline monohydrochloride
Xylometazolinum
Xylomethazoline
|
|
16 |
|
Mecobalamin |
Approved, Investigational |
Phase 3 |
|
13422-55-4 |
|
Synonyms:
ASIMIL B-12
B-MAX
CO-METHYLCOBALAMIN
MeCbl
Mecobalamin
Mecobalamina
|
Mecobalaminum
Methyl vitamin B12
Methyl(III)cobalamin
Methylcob(III)alamin
Methylcobalamin
|
|
17 |
|
Hydroxocobalamin |
Approved |
Phase 3 |
|
13422-51-0 |
15589840 44475014 |
Synonyms:
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
ALPHAREDISOL
Axlon
Ciplamin H
Cobalex
Cobalin H
COBALIN-H
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Codroxomin
CYANOKIT
Docclan
Docelan
Docevita
Droxomin
Ducobee hy
Duradoce
|
Duralta-12
HEPAVIT
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxo-cobalamin
HYDROXOCOBALAMIN ACETATE
HYDROXOCOBALAMIN ANHYDROUS
Hydroxocobalamine
HYDROXOCOBALAMINUM ANHYDROUS
HYDROXOCOBEMINE
Hydroxomin
Hydroxycobalamin
MEGAMILBEDOCE
NEO-CYTAMEN
OH-CBL
Vitamin b-12b
|
|
18 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
19 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 3 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
20 |
|
Cyanocobalamin |
Approved, Nutraceutical |
Phase 3 |
|
68-19-9 |
24892734 16212801 44176380 |
Synonyms:
Anacobin
Bedoz
BEHEPAN
Berocca PN
Berubigen
BETALIN 12
Betalin 12 crystalline
Betaline-12
Betolvex
Bevidox
Bevidox concentrate
Biocobalamine
Byladoce
Cabadon m
CALOMIST
Cernevit-12
Cianocobalamina
Cobadoce forte
Cobalin
Cobavite
Cobex
Cobolin-M
Copharvit 5000
Covit
Crystamin
Crystamine
Crysti-12
Crystimin
Crystwel
Cyano-b12
Cyanobalamin concentrate
Cyanocob(III)alamin
CYANOCOBALAMIN
Cyanocobalamin (JP15/usp)
Cyanocobalamin Co 57 Schilling Test Kit
Cyanocobalamine
Cyanocobalaminum
Cyanocobalmin
Cyanoject
CYANOVIT-B12
Cycobemin
Cycolamin
Cykobemin
Cykobeminet
Cyomin
Cyredin
Cytacon
Cytamen
Cytobion
Depinar
Dicopac
Dicopac Kit
Dimethylbenzimidazoylcobamide
Distivit
Docemine
Docibin
Docivit
Dodecabee
Dodecavite
Dodex
Duodecibin
Embiol
Emociclina
Eritrone
|
Erycytol
Erythrotin
Euhaemon
Extrinsic factor
Factor II
Fermin
Fresmin
Hemomin
Hepagon
Hepavis
Hepcovite
Hylugel plus
Infuvite Pediatric
Lactobacillus lactis dorner factor
M.V.I. Pediatric
Macrabin
Megabion
Megalovel
Milbedoce
Millevit
Nagravon
Nascobal
Neuroforte-R
Normocytin
Novidroxin
NSC-80365
Pernaemon
Pernaevit
Pernipuron
Plecyamin
Poyamin
Primabalt
Rebramin
Redamina
Redisol
Rhodacryst
Rubesol
RUBIVITE
Rubramin
RUBRAMIN PC
Rubratope-57 Kit
Rubratope-60 Kit
Rubripca
Rubrocitol
RUVITE
Shovite
Sytobex
Vibal
Vibalt
Vibisone
Virubra
Vitabee 12
VITAMIN B 12
Vitamin b12
Vitamin b12 complex
VITAMIN B12 NOS
Vitamin b12 preparation
vitamine b12
Vitaped
Vitarubin
Vita-rubra
Vitral
VI-TWEL
|
|
21 |
|
Cobalamin |
Experimental |
Phase 3 |
|
13408-78-1 |
6857388 |
Synonyms:
5,6-Dimethyl-1-a-D-ribofuranosyl-1H-benzimidazole
5,6-Dimethyl-1-a-D-ribofuranosylbenzimidazole
5,6-Dimethyl-1-alpha-delta-ribofuranosyl-1H-benzimidazole
5,6-Dimethyl-1-alpha-delta-ribofuranosylbenzimidazole
a-(5,6-Dimethylbenzimidazolyl)cobamide
alpha-(5,6-Dimethylbenzimidazolyl)cobamide
b 12, Vitamin
b12, Vitamin
Cbl
Cob(III)alamin
Cobalamin (III)
Cobalamin(1+)
Cobalamin(III)
Cobalamine
|
Cobalamins
Cobinamide ion(1+) dihydrogen phosphate (ester) inner salt 3'-ester
Cobinamide ion(1+) dihydrogen phosphate (ester) inner salt 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosyl-1H-benzimidazole
Cyanocobalamin
Eritron
Hydroxomin
Rubivite
Rubratope-57
Rubratope-60
Ruvite
Vitamin b 12
Vitamin b12
Α-(5,6-dimethylbenzimidazolyl)cobamide
|
|
22 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Mitogens |
|
Phase 3 |
|
|
|
26 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
27 |
|
Protective Agents |
|
Phase 3 |
|
|
|
28 |
|
Shark Cartilage |
|
Phase 3 |
|
|
|
29 |
|
2,2'-dithiodiethanesulfonic acid |
|
Phase 3 |
|
|
65626 |
Synonyms:
(S-CoM)2
2,2'-Dithiodiethanesulfonate
2,2'-Dithiodiethanesulfonic acid
2,2'-Dithiodiethanesulfonic acid, ammonium salt
2,2'-Dithiodiethanesulfonic acid, disodium salt
2,2'-Dithiodiethanesulphonate
2,2'-Dithiodiethanesulphonic acid
|
2-[(2-Sulfoethyl)disulfanyl]ethane-1-sulfonate
2-[(2-Sulphoethyl)disulphanyl]ethane-1-sulphonate
2-[(2-Sulphoethyl)disulphanyl]ethane-1-sulphonic acid
Coenzyme m
Dimesna
Disodium 2,2'-dithio-bis-ethane sulfonate
Tavocept
|
|
30 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
31 |
|
Anesthetics |
|
Phase 3 |
|
|
|
32 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
33 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
34 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
35 |
|
Folate |
|
Phase 3 |
|
|
|
36 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
37 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
38 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
39 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
40 |
|
Vitamins |
|
Phase 3 |
|
|
|
41 |
|
Vitamin B12 |
|
Phase 3 |
|
|
|
42 |
|
Vitamin B 12 |
|
Phase 3 |
|
|
|
43 |
|
Nedaplatin |
Approved, Investigational |
Phase 2 |
|
95734-82-0 |
|
Synonyms:
(glycolato-O,O')diammineplatinum(II)
CDGP
cis-Diammine (glycolato)platinum
|
cis-diammine(glycolato)platinum
cis-Diammine(glycolato)platinum(II)
Nedaplatin
|
|
44 |
|
Cathine |
Approved, Experimental, Illicit, Vet_approved, Withdrawn |
Phase 2 |
|
14838-15-4, 492-39-7 |
131954576 4786 26934 |
Synonyms:
(+-)-Norephedrine
(+)-Norpseudoephedrine
(+-)-Phenylpropanolamine
2-AMINO-1-PHENYLPROPAN-1-OL
Cathina
Cathine
Cathinum
D-Cathine
Dexatrim
DL-Norephedrine
DL-Phenylpropanolamine
D-Norephedrine
d-Norpseudoephedrine
d-Nor-psi-ephedrine
FENILPROPANOLAMINA
Hydriatine
Hydrochloride, phenylpropanolamine
Katine
L-NOREPHEDRINE
L-Phenyl propanolamine
|
Mucorama
Nobese
NOREPHEDRIN
Norephedrine
Obestat
PHENYLPROPANOLAMIN
Phenylpropanolamina
Phenylpropanolamine
PHÉNYLPROPANOLAMINE
Phenylpropanolamine hydrochloride
PHENYLPROPANOLAMINUM
PPA
Prestwick_388
Prolamine
Propadrine
Propagest
Pseudonorephedrine
psi-Norephedrine
Triaminic DM
Β-HYDROXYAMPHETAMINE
|
|
45 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 2 |
|
93-14-1 |
3516 |
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
AMONIDRON
Aresol
Benylin-e
Breonesin
Bronchol
CVT-2534
Ether, guaiacol glyceryl
FAMEL
FRANOLYN CHESTY
GECOLATE
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
Glycerylguaiacol
|
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
GUAIFENESIN OR GUAIPHENESIN
Guaifenesina
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
HUMABID
Humibid
Hustosil
Hytuss
LIQUFRUTA
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
MUCINEX
NIROLEX FOR CHESTY COUGH DECONGESTANT
NSC-62112
O-Methoxyphenyl glyceryl ether
Organidin NR
p-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
TIXYLIX CHESTY COUGH
|
|
46 |
|
Trametinib |
Approved |
Phase 1, Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
47 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
48 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
49 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
50 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
Interventional clinical trials:
(show top 50)
(show all 257)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation |
Unknown status |
NCT02283424 |
Phase 4 |
Icotinib;chemotherapy (Carboplatin and Docetaxel) |
2 |
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study |
Unknown status |
NCT02103257 |
Phase 4 |
Sequential Icotinib Plus Chemotherapy;Icotinib |
3 |
Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative |
Unknown status |
NCT02804646 |
Phase 4 |
recombinant human endostatin;pemetrexed plus cisplatin or carboplatin |
4 |
Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma |
Unknown status |
NCT01665417 |
Phase 4 |
Experimental;Chemotherapy |
5 |
Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma |
Unknown status |
NCT02399566 |
Phase 4 |
Erlotinib, Pemetrexed |
6 |
Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations |
Completed |
NCT01609543 |
Phase 4 |
erlotinib [Tarceva] |
7 |
Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion |
Unknown status |
NCT02011997 |
Phase 3 |
|
8 |
A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma |
Unknown status |
NCT02281708 |
Phase 3 |
vinorelbine plus cisplatin |
9 |
Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma |
Unknown status |
NCT02518802 |
Phase 3 |
Gefitinib;Pemetrexed |
10 |
Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation |
Unknown status |
NCT02929693 |
Phase 3 |
gefitinib;Yiqi-yangyin-jiedu decoction;placebo |
11 |
Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation |
Completed |
NCT01719536 |
Phase 3 |
Icotinib;Chemotherapy |
12 |
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect |
Completed |
NCT05204758 |
Phase 3 |
TCM Formula;Placebo |
13 |
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer |
Completed |
NCT00020709 |
Phase 3 |
cisplatin;docetaxel;etoposide;gefitinib |
14 |
Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC |
Completed |
NCT00021060 |
Phase 2, Phase 3 |
paclitaxel;carboplatin |
15 |
Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer |
Completed |
NCT00005838 |
Phase 3 |
shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel |
16 |
A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG |
Completed |
NCT00002852 |
Phase 3 |
paclitaxel;carboplatin |
17 |
A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer |
Completed |
NCT00049543 |
Phase 3 |
gefitinib |
18 |
Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin |
Completed |
NCT00966914 |
Phase 3 |
Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel |
19 |
Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial |
Completed |
NCT02889692 |
Phase 3 |
YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib® |
20 |
A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung |
Completed |
NCT00455936 |
Phase 3 |
Gefitinib |
21 |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer |
Recruiting |
NCT04929041 |
Phase 2, Phase 3 |
Carboplatin;Nab-paclitaxel;Paclitaxel;Pemetrexed |
22 |
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study |
Recruiting |
NCT04339218 |
Phase 3 |
Pembrolizumab;Pemetrexed;Carboplatin |
23 |
Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence |
Recruiting |
NCT03380468 |
Phase 2, Phase 3 |
cisplatin plus pemetrexed |
24 |
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) |
Recruiting |
NCT03391869 |
Phase 3 |
|
25 |
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
NCT00946712 |
Phase 3 |
Carboplatin;Paclitaxel |
26 |
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT03676192 |
Phase 3 |
CT-16;Avastin |
27 |
Tyrosine-kinase Inhibitor (TKI) With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma |
Terminated |
NCT02893332 |
Phase 3 |
TKI (Gefitinib or Tarceva ) |
28 |
A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma |
Terminated |
NCT01798485 |
Phase 3 |
Docetaxel;Ganetespib |
29 |
Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases |
Terminated |
NCT02162537 |
Phase 3 |
Cisplatin;Pemetrexed;Bevacizumab |
30 |
Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial |
Unknown status |
NCT04310943 |
Phase 2 |
Tislelizumab |
31 |
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial |
Unknown status |
NCT03728374 |
Phase 2 |
Anlotinib |
32 |
An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation. |
Unknown status |
NCT02036359 |
Phase 2 |
erlotinib;docetaxel |
33 |
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma |
Unknown status |
NCT02980991 |
Phase 2 |
Pemetrexed;Cisplatin |
34 |
A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung Adenocarcinoma |
Unknown status |
NCT03904563 |
Phase 2 |
Bevacizumab;concurrent chemotherapy |
35 |
High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases |
Unknown status |
NCT02284490 |
Phase 2 |
pemetrexed |
36 |
A Single-Armed Phase II Study of Radiation and Bevacizumab Maintenance Therapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene |
Unknown status |
NCT03905317 |
Phase 2 |
Bevacizumab Injection;concurrent chemotherapy |
37 |
Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial |
Unknown status |
NCT02951637 |
Phase 2 |
Pemetrexed plus carboplatin combined with gefitinib;Gefitinib |
38 |
Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. |
Unknown status |
NCT02704767 |
Phase 2 |
Apatinib;Tarceva;Placebo |
39 |
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma |
Unknown status |
NCT02146118 |
Phase 2 |
Erlotinib |
40 |
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm |
Unknown status |
NCT03254004 |
Phase 2 |
Pembrolizumab |
41 |
Effectiveness and Safety of Adding Bevacizumab to Chemotherapy in Patients With Advanced Lung Adenocarcinoma With Stable Disease After 2 Cycles of First Line Combination Chemotherapy: a Multicenter, Prospective Cohort Study |
Unknown status |
NCT03240549 |
Phase 2 |
bevacizumab |
42 |
A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma |
Unknown status |
NCT03376737 |
Phase 2 |
Apatinib |
43 |
Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations |
Unknown status |
NCT01131429 |
Phase 2 |
Erlotinib;Docetaxel;Cisplatin |
44 |
The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar |
Unknown status |
NCT01564329 |
Phase 2 |
endostar |
45 |
A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers |
Unknown status |
NCT01502202 |
Phase 2 |
Gefitinib;Placebo;Pemetrexed plusCIsplatin |
46 |
Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) |
Unknown status |
NCT02946359 |
Phase 2 |
Crizotinib, bevacizumab |
47 |
A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy |
Unknown status |
NCT02787447 |
Phase 2 |
TKI;Thymosin Alpha 1 |
48 |
A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation |
Unknown status |
NCT02737774 |
Phase 2 |
Icotinib;Pemetrexed/Carboplatin |
49 |
A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy |
Unknown status |
NCT02788058 |
Phase 2 |
EGFR-TKI |
50 |
An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations |
Unknown status |
NCT03486496 |
Phase 2 |
gefitinib;Berberine |
|